CIK 0001829802 · <br>Emerging growth company
Faeth Therapeutics, Inc.
Sign in to watch- Ticker
- FTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 512-200-2982
- Business address
- 701 TILLERY STREET #12 #1010, AUSTIN, TX, 78702
- Former names
- Sensei Biotherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-07-10 | Cambrian BioPharma Inc 10% owner | Grant or award | +4,466 | 5,240,422 | ||
| 2023-07-10 | Cambrian BioPharma Inc 10% owner | Grant or award · Stock Option (Right to Buy) | +14,550 | 14,550 | ||
| 2023-06-01 | Apeiron Investment Group Ltd. 10% owner | Sale | −2,485,923 | $1.58 | $3.9M | 0 |
| 2023-06-01 | Apeiron Investment Group Ltd. 10% owner | Sale | −955,738 | $1.58 | $1.5M | 0 |
| 2023-02-23 | Apeiron Investment Group Ltd. 10% owner | Purchase | +1,100 | $1.62 | $2K | 2,484,823 |
| 2023-02-23 | Apeiron Investment Group Ltd. 10% owner | Purchase | +1,100 | $1.60 | $2K | 2,485,923 |
| 2023-02-15 | Gallagher Patrick Stephen Chief Business Officer | Shares withheld for taxes | −9,383 | $1.50 | $14K | 34,130 |
| 2023-02-15 | van der Horst Edward Chief Scientific Officer | Shares withheld for taxes | −9,525 | $1.50 | $14K | 52,913 |
| 2023-02-15 | Celebi John President and CEO | Shares withheld for taxes | −20,492 | $1.50 | $31K | 110,811 |
| 2023-02-15 | Colgan Erin Chief Financial Officer | Shares withheld for taxes | −10,943 | $1.50 | $16K | 68,089 |
| 2023-02-15 | Colgan Erin Chief Financial Officer | Grant or award | +30,046 | 57,732 | ||
| 2023-02-15 | Colgan Erin Chief Financial Officer | Grant or award | +21,300 | 79,032 | ||
| 2023-02-15 | Colgan Erin Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2023-02-15 | Celebi John President and CEO | Grant or award | +51,893 | 110,003 | ||
| 2023-02-15 | Celebi John President and CEO | Grant or award | +21,300 | 131,303 | ||
| 2023-02-15 | Celebi John President and CEO | Grant or award · Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2023-02-15 | Gallagher Patrick Stephen Chief Business Officer | Grant or award | +29,313 | 29,313 | ||
| 2023-02-15 | Gallagher Patrick Stephen Chief Business Officer | Grant or award | +14,200 | 43,513 | ||
| 2023-02-15 | Gallagher Patrick Stephen Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2023-02-15 | van der Horst Edward Chief Scientific Officer | Grant or award | +23,565 | 44,738 |
Page 10 of 12 · 238 trades